Boston Scientific Corporation has said its Synergy Everolimus-Eluting Stent System has proved just as safe and effective as its Promus version in treating de novo coronary artery lesions.

"Our fourth-generation SYNERGY Stent is designed to offer the performance advantages of our innovative platinum chromium platform, while significantly reducing the amount of polymer and drug to which the vessel wall is exposed," explained Dr Keith Dawkins, senior vice-president and chief medical officer of Boston Scientific's Cardiology, Rhythm and Vascular Group.

The data from the trial will be used to support the firm's application for CE Mark approval, which the Promus platform has achieved. Currently, both are approved only as investigational devices in the US.

Professor Ian T Meredith, director of MonashHeart in Melbourne, Australia, commented: "The Synergy Stent ... appears to be safe with very low rates of myocardial infarction and revascularisation and no reported cardiac deaths or stent thrombosis."

The stent is designed to address potential limitations with durable polymer coatings used on currently available drug-eluting stents, which may be associated with chronic inflammation and impaired healing.

Professor Meredith added: "The impressive clinical and angiographic results ... bode well for this innovative new coronary stent technology."

Source:

Boston Scientific SYNERGY™ Stent Demonstrates Comparable Safety and Effectiveness Outcomes Versus PROMUS Element™ Platinum Chromium Stent (11/11/11) 

© Adfero Ltd